Siemens Healthineers AGMEX:SHL N 72 EBITDA Margin % is 17.66% as of Mar. 2026, which is 10% below its 10-year median of 19.61. GuruFocus rates MEX:SHL N with a GF Score™ of 72/100 and a GF Value™ of MXN1,405.64. The stock has 5 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Siemens Healthineers AG ranks better than 73.77% on this metric.
Siemens Healthineers AG (MEX:SHL N) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Siemens Healthineers AG EBITDA Margin % Related Terms
Siemens Healthineers AG EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:SHL N vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Siemens Healthineers AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Siemens Healthineers AG EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Siemens Healthineers AG's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Siemens Healthineers AG's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Siemens Healthineers AG (MEX:SHL N) has a EBITDA Margin % of 17.66% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Siemens Healthineers AG and its competitors. This is 10% below median its historical median of 19.61. Over the past decade, Siemens Healthineers AG's EBITDA Margin % has ranged from 17.44 to 20.59. According to the industry distribution chart, Siemens Healthineers AG ranks #214 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 26.2%.
Is Siemens Healthineers AG's EBITDA Margin % too high?
Siemens Healthineers AG's current EBITDA Margin % of 17.66% is 10% below median its 10-year median of 19.61. Over the past 10 years, this metric has ranged from a low of 17.44 to a high of 20.59. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Siemens Healthineers AG's value of 17.66% is 136.3% above this industry median. Based on the distribution chart, Siemens Healthineers AG ranks #214 out of 816 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Siemens Healthineers AG has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Siemens Healthineers AG's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Siemens Healthineers AG ranks #214 out of 816 companies for EBITDA Margin %. This puts Siemens Healthineers AG in the upper half of its industry. The industry median EBITDA Margin % is 7.48. Siemens Healthineers AG's value of 17.66% is 136.3% above this benchmark. Historically, Siemens Healthineers AG's own EBITDA Margin % has ranged from 17.44 to 20.59 over the past decade. While the company's 10-year median is 19.61 vs. the industry median of 7.48, Siemens Healthineers AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Siemens Healthineers AG's current EBITDA Margin % of 17.66% is 136.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Siemens Healthineers AG and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Siemens Healthineers AG's current EBITDA Margin % is 17.66%, which is 10% below median its own 10-year median of 19.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Siemens Healthineers AG stock overvalued right now?
Siemens Healthineers AG (MEX:SHL N) has a current EBITDA Margin % of 17.66%. The stock's GF Value™ is MXN1,405.64, compared to a current price of MXN918.93 — trading 34.6% below its estimated fair value. The current EBITDA Margin % is 17.66%, which is 10% below median its 10-year median of 19.61 and 136.3% above the Medical Devices & Instruments industry median of 7.48. Siemens Healthineers AG's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Siemens Healthineers AG (MEX:SHL N), the current EBITDA Margin % is 17.66% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Siemens Healthineers AG (MEX:SHL N) Overvalued in 2026?
Based on GuruFocus' analysis, Siemens Healthineers AG stock appears to be undervalued.
The current stock price of MXN918.93 is trading 34.6% below its estimated GF Value™ of MXN1,405.64.
Key valuation signals for MEX:SHL N:
EBITDA Margin %: 17.66% (10% below median its 10-year median of 19.61)
GF Value™: MXN1,405.64 vs. price of MXN918.93 (34.6% below fair value)
Industry Position: 136.3% above the Medical Devices & Instruments median (#214 of 816)
No single metric tells the full story. See the MEX:SHL N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Siemens Healthineers is engaged in therapeutic imaging, radiotherapy, laboratory, and point-of-care diagnostics. The imaging segment (56% of sales in fiscal 2025) includes magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound. The Varian segment (18% of sales) offers radiotherapy and other oncology solutions. The diagnostics segment (19%) includes in vitro diagnostics and point-of-care diagnostics. The advanced therapies (now part of precision therapy) segment (9%) products are designed to support image-guided minimally invasive treatments in cardiology, interventional radiology, and surgery. The Americas represents 44% of total sales, Europe, Middle East, and Africa 32%, and Asia-Pacific, including China (11%), the remainder.
72GF Score
Get the complete analysis for MEX:SHL N
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:SHL N has been successfully added to your 
